Targeted Chemotherapy Efficacy of the ZHER2:V2-pemetrexed for HER2-positive Lung Adenocarcinoma and Molecular Imaging Evaluation

Conclusions: The ZHER2:V2-pemetrexed conjugates showed promising targeted antitumor activity against HER2-positive lung adenocarcinoma with reduced side effects compared with pemetrexed. ZHER2:V2-pemetrexed is a novel molecular probe with great clinical potential for diagnosis and treatment. Keywords: HER2, affibody, 99mTc-ZHER2:V2-pemetrexed, molecular imaging, therapeutic response. This study was supported by the funds (NO. 81571702) from the National Natural Science Foundation of China project.

Source: Journal of Nuclear Medicine - May 20, 2019 Category: Nuclear Medicine Authors: Han, J., Zhao, X., Ma, T., Liu, J., Zhang, Z., Zhang, J., Wang, J. Tags: Other Solid Tumors (Diagnosis) Source Type: research